BeyondSpring Inc. (BYSI): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 17:27 ET
- Event date
- 2026-11-13
- Accession no.
- 0001171843-26-007431
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
BeyondSpring reports quarterly results, FDA Fast Track designation and subsidiary sale
BeyondSpring reported a $2.1 million net loss from continuing operations for the quarter ended September 30, 2026, compared to $1.6 million a year earlier. It also disclosed FDA Fast Track designation for Plinabulin plus docetaxel and the completed sale of BeyondSpring Ltd. to Biolin. As non-cash consideration, Biolin will support DUBLIN-4 activities in China expected to include approximately 221 patients.
- Quarterly net loss from continuing operations was $2.1 million, compared to $1.6 million in the prior-year quarter.
- Cash, cash equivalents, and short-term investments were $0.6 million as of September 30, 2026.
- The FDA granted Fast Track designation to Plinabulin plus docetaxel for a previously treated non-squamous NSCLC population.
- BeyondSpring sold BeyondSpring Ltd. to Biolin on September 30, 2026; Biolin will support DUBLIN-4 activities in China.
earningsregulatoryasset sale
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | f8k_111326.htm |
| EX-99.1 | PRESS RELEASE | exh_991.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.